Sign in:
Email
 Password  save:
  
 Company Reports 
 
   
My Recent Searches
  Help
 
   
 
 
Get Insiders for : 
Biomarin Pharmaceutical Inc (BMRN)  
$88.61 0.87 (0.99%) as of 4:30 Wed 3/27


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 188,370,000
Market Cap: 16.69(B)
Last Volume: 1,031,697 Avg Vol: 1,398,626
52 Week Range: $76.22 - $100.3
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Drug Manufacturers - Other

Member Indexes:

    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:

     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  811
Guru Rank Value     : 0.9
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.


 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 3,625
Total Buy Value $0 $0 $0 $314,469
Total People Bought 0 0 0 1
Total Buy Transactions 0 0 0 1
Total Shares Sold 92,341 116,105 269,465 610,463
Total Sell Value $8,237,699 $10,489,308 $24,880,826 $57,517,351
Total People Sold 3 4 5 8
Total Sell Transactions 9 11 22 59
End Date 2023-12-28 2023-09-26 2023-03-28 2022-03-28

   
Records found: 1283
  Page 4 of 52  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

 
3m +/-  
Form
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2014-04-30 4 A $29.69 $21,228 D/D 715 195,235     -
   Ajer Jeffrey Robert SVP, Chief Commercial Of   •       –      –    2014-04-30 4 A $29.70 $19,780 D/D 666 26,046     -
   Fuchs Henry J EVP, Chief Medical Officer   •       –      –    2014-04-30 4 A $29.69 $21,228 D/D 715 74,565     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2014-03-28 4 OE $12.99 $25,980 I/I 2,000 48,740     -
   Slamon Dennis Director   –       •      –    2014-03-19 4 A $0.00 $0 D/D 4,000 4,700     -
   Slamon Dennis Director   –       •      –    2014-03-19 3 IO $0.00 $0 D/D 0 700     -
   Ajer Jeffrey Robert SVP, Chief Commercial Of   •       –      –    2014-03-06 4 AS $78.63 $1,365,831 D/D (17,370) 25,380     -
   Ajer Jeffrey Robert SVP, Chief Commercial Of   •       –      –    2014-03-06 4 OE $21.51 $473,165 D/D 17,370 42,750     -
   Spiegelman Daniel K EVP, Chief Financial Officer   •       –      –    2014-03-05 4 S $82.93 $995 D/D (12) 68,748     -
   Spiegelman Daniel K EVP, Chief Financial Officer   •       –      –    2014-03-03 4 AS $80.32 $642,530 D/D (8,000) 64,273     -
   Spiegelman Daniel K EVP, Chief Financial Officer   •       –      –    2014-03-03 4 OE $39.06 $312,480 D/D 8,000 72,273     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2014-02-20 4 AS $80.00 $640,000 I/I (8,000) 46,740     -
   Davis George Eric SVP, General Counsel   •       –      –    2014-02-20 4 AS $80.00 $1,600,000 D/D (20,000) 60,656     -
   Davis George Eric SVP, General Counsel   •       –      –    2014-02-20 4 OE $21.51 $430,200 D/D 20,000 80,656     -
   Fuchs Henry J EVP, Chief Medical Officer   •       –      –    2014-02-14 4 A $0.00 $0 D/D 31,500 73,850     -
   Ajer Jeffrey Robert SVP, Chief Commercial Of   •       –      –    2014-02-14 4 A $0.00 $0 D/D 10,500 25,380     -
   Spiegelman Daniel K EVP, Chief Financial Officer   •       –      –    2014-02-14 4 A $0.00 $0 D/D 26,250 64,273     -
   Davis George Eric SVP, General Counsel   •       –      –    2014-02-14 4 A $0.00 $0 D/D 10,500 60,656     -
   Baffi Robert EVP, Technical Operations   •       –      –    2014-02-14 4 A $0.00 $0 D/D 26,250 86,600     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2014-02-14 4 A $0.00 $0 D/D 78,750 194,520     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2014-02-06 4 OE $12.99 $51,960 I/I 4,000 54,740     -
   Baffi Robert EVP, Technical Operations   •       –      –    2014-02-04 4 GA $0.00 $0 I/I 2,675 13,722     -
   Baffi Robert EVP, Technical Operations   •       –      –    2014-02-04 4 GD $0.00 $0 D/D 2,675 60,350     -
   Fuchs Henry J EVP, Chief Medical Officer   •       –      –    2014-02-03 4 AS $67.70 $676,966 D/D (10,000) 42,350     -
   Fuchs Henry J EVP, Chief Medical Officer   •       –      –    2014-02-03 4 OE $21.51 $215,100 D/D 10,000 52,350     -

  1283 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 4 of 52
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed